Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular TherapeutixTM Reports on Topline Results of Phase 2b Glaucoma Clinical Trial

Business Wire October 22, 2015

Ocular Therapeutix(TM) Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA(TM) for the Treatment of Allergic Conjunctivitis

Business Wire October 22, 2015

Ocular Therapeutix(TM) Begins Enrollment in Third Phase 3 Clinical Trial for DEXTENZA(TM) for the Treatment of Post-Surgical Ocular Inflammation and Pain

Business Wire October 14, 2015

Ocular Therapeutix(TM) Submits New Drug Application to U.S. Food and Drug Administration for DEXTENZA® for the Treatment of Post-Surgical Ocular Pain

Business Wire September 28, 2015

Ocular Therapeutix Expands Its Board of Directors with the Appointment of Renowned Retinal Specialist Jeffrey S. Heier, M.D.

Business Wire September 14, 2015

Ocular Therapeutix(TM) to Participate in Two Investor Conferences in September 2015

Business Wire September 3, 2015

Ocular Therapeutix(TM) Reports Second Quarter 2015 Financial Results

Business Wire August 10, 2015

Ocular Therapeutix(TM) to Report Second Quarter 2015 Financial Results

Business Wire August 3, 2015

Ocular Therapeutix(TM) to Participate at the Cantor Fitzgerald Inaugural Healthcare Conference

Business Wire June 30, 2015

Ocular Therapeutix(TM) Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA(TM) for the Treatment of Allergic Conjunctivitis

Business Wire June 16, 2015

Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock

Business Wire June 4, 2015

Ocular Therapeutix, Inc. Announces Proposed Public Offering of Common Stock

Business Wire June 2, 2015

Ocular TherapeutixTM Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results

Business Wire May 15, 2015

Ocular Therapeutix(TM) to Report First Quarter 2015 Financial Results

Business Wire May 6, 2015

Ocular Therapeutix to Present Eight Posters Highlighting its Sustained Release Hydrogel Platform Technology at the Association for Research in Vision and Ophthalmology Annual Meeting

Business Wire May 1, 2015

Ocular Therapeutix(TM) Reports Topline Clinical Data for its Second Phase 3 Clinical Trial Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain

Business Wire April 6, 2015

Ocular Therapeutix(TM) Reports Fourth Quarter and Full Year 2014 Financial Results

Business Wire March 10, 2015

Ocular Therapeutix(TM) Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain

Business Wire March 10, 2015

Ocular Therapeutix(TM) to Report Fourth Quarter and Full Year 2014 Financial Results

Business Wire March 3, 2015

Ocular Therapeutix(TM) to Participate in Two Upcoming Investor Conferences

Business Wire February 19, 2015